Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Congress Scientific Watch

The Congress Scientific Watch provides ESMO Members with fresh comments and analysis from selected abstracts presented during major international Oncology meetings.

Login to start reading, or Join ESMO - All articles are Open Access after 6 months.

Filter by:

58 results

Cancer in Older Adults;  Immunotherapy;  Cytotoxic Therapy;  Hodgkin Lymphoma

Nivolumab Combination Improves Outcomes In Older Advanced Hodgkin’s Lymphoma Patients

From the 65th American Society of Hematology Annual Meeting:
Switching from brentuximab vedotin to nivolumab alongside chemotherapy increased progression-free survival and reduced toxicity in patients aged 60 years and older with classic Hodgkin’s lymphoma

Targeted Therapy;  Chronic Lymphocytic Leukaemia;  Lymphomas

Extended ALPINE Follow-Up Confirms Zanubrutinib PFS Superiority

From the 65th American Society of Hematology Annual Meeting:
Patients given zanubrutinib for relapsed/refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma continue to have better PFS than their ibrutinib-treated counterparts after 3 years

Endocrine Therapy;  Targeted Therapy;  Molecular Oncology;  Breast Cancer

Inavolisib Addition Boosts PFS For High-Risk PIK3CA-Mutated Advanced Breast Cancer

From San Antonio Breast Cancer Symposium 2023:
Combining palbociclib plus fulvestrant with inavolisib significantly improves progression-free survival for patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced breast cancer  

Immunotherapy;  Cytotoxic Therapy;  Breast Cancer

Chemotherapy De-Escalation May Be Feasible For Immune-Enriched Early TNBC

From San Antonio Breast Cancer Symposium 2023:
Patients with early-stage triple-negative breast cancer who have high tumour infiltrating lymphocytes or PD-L1-positive disease may not require a full course of neoadjuvant immunochemotherapy  

Targeted Therapy;  Cytotoxic Therapy;  Immunotherapy;  Chronic Lymphocytic Leukaemia

MRD-Guided Ibrutinib–Venetoclax Improves CLL Outcomes Over Chemoimmunotherapy

From the 65th American Society of Hematology Annual Meeting:
Patients with chronic lymphocytic leukaemia treated with ibrutinib–venetoclax beyond undetectable measurable residual disease have a lower risk of progression or death than those given fludarabine–cyclophosphamide–rituximab

Targeted Therapy;  Molecular Oncology;  Breast Cancer

Tucatinib Plus T-DM1 Boosts HER2-Positive Advanced Breast Cancer PFS

From San Antonio Breast Cancer Symposium 2023:
The HER2CLIMB-02 trial findings support the addition of tucatinib to T-DM1 for patients with previously treated, locally advanced or metastatic, HER2-positive breast cancer  

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.